Monday
16.00 - 18.00 CET
Vienna
Advancing diabetes treatment: new standards in patient-centered care
INCREASING OPPORTUNITY FOR INDIVIDUALISED CARE WITH AN ORAL GLP-1RA
Filip Knop (Denmark)
Welcome
Tina Vilsbøll (Denmark)
Innovation in the GLP-1RA landscape: expanding options for individualised care
Juris Meier (Germany)
An oral GLP-1RA in the incretin landscape
Richard Pratley (USA)
Navigating the evolving treatment landscape: head-to-head comparisons
Ofri Mosenzon (Israel)
The vulnerable patient: the use of semaglutide in renal impairment and late stage disease
Stephen Bain (UK)
Diving deeper into the PIONEER programme: exploring different patient populations
All
Clinical perspectives: an oral GLP-1RA to individualise diabetes treatment
BEYOND GLYCAEMIC CONTROL: NEW DIRECTIONS IN PATIENT-CENTERED CARE
Filip Knop (Denmark)
Welcome Back
Alice Cheng (Canada)
Across the continuum of care: efficacy with once-weekly semaglutide
David Strain (UK)
Cardiovascular benefit: a closer look at semaglutide and the evolution of treatment guidelines
All
Clinical perspectives: implications of evolving guidelines for patient care
INNOVATIONS IN INSULIN TREATMENT: NEW OPPORTUNITIES FOR PATIENT-CENTERED CARE
Eden Miller (USA)
Glycaemic variability with basal insulins: have we conquered hypoglycaemia?
Julio Rosenstock (USA)
Raising the bar for innovation with weekly basal insulin
All
Clinical perspectives: what does innovation in insulin therapy mean for patient outcomes?
Symposium by:
Novo Nordisk A/S